Metabolic syndrome in bipolar disorder: Findings from the bipolar disorder center for Pennsylvanians

Bipolar Disorders

Volumn 7, Issue 5, 2005, Pages 424-430

  Fagiolini, Andrea ^a   Frank, Ellen ^a   Scott, John A ^a   Turkin, Scott ^a   Kupfer, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bipolar disorder; Cholesterol; Diabetes; Metabolic syndrome; Obesity; Triglycerides

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPNOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMEN; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA ANALYSIS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESPAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POPULATION RESEARCH; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SAMPLING; STATISTICAL ANALYSIS; SUICIDE ATTEMPT; TREATMENT PLANNING; UNITED STATES;

ACADEMIC MEDICAL CENTERS; BIPOLAR DISORDER; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; OBESITY; PENNSYLVANIA;

EID: 26444447991     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2005.00234.x     Document Type: Article

References (38)

1. Nasrallah HA, Newcomer JJW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24: S7-S14.
2. Fagiolini A, Frank E, Houck PR et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63: 528-533.
3. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 112-117.
4. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004; 65: 634-651.
5. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64: 1426-1435.
6. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003; 64: 532-539.
7. McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207-213.
8. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61: 179-184.
9. Kilbourne AM, Cornelius JR, Han X et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6: 368-373.
10. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003; 48: 458-461.
11. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26.
12. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-1420.
13. Russell JD, Johnson GF. Affective disorders, diabetes mellitus and lithium. Aust N Z J Psychiatry 1981; 15: 349-353.
14. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980; 21: 270-275.
15. Sobczak S, Honig A, Christophe A et al. Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol Med 2004; 34: 103-112.
16. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Bayik Y. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002; 46: 176-179.
17. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 217-234.
18. Yates WR, Wallace R. Cardiovascular risk factors in affective disorder. J Affect Disord 1987; 12: 129-134.
19. Basu R, Brar JS, Chengappa KNR et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord 2004; 6: 314-318.
20. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
21. Executive Summary: The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
22. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
23. Bonora E, Targher G, Formentini G et al. The metabolic syndrome is an independent predictor of the cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21: 52-58.
24. Alexander C, Landsman P, Teutsch S, Haffner S. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
25. Laaksonen D, Lakka H-M, Niskanen L, Kaplan G, Salonen J, Lakka T. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-1077.
26. Ford E, Giles W, Mokdad A. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-2449.
27. Post R, Leverich GS, Nolen WA et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2003; 5: 396-406.
28. Fagiolini A, Kupfer DJ, Rucci P, Scott J, Novick D, Frank EF. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry 2004; 65: 509-514.
29. Kinder L, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004; 66: 316-322.
30. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among U.S. adults, 1999-2000. JAMA 2002; 288: 1723-1727.
31. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108: 1546-1551.
32. Lempiäinen P, Mykkänen L, Pyöröö K et al, Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100: 123-128.
33. Haffner SM. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med 1997; 14: S12-S18.
34. Ashley FW Jr, Kannel WB. Relation of weight change to changes in atherogenic traits: the Framingham Study. J Chronic Dis 1974; 27: 103-114.
35. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes 1997; 21: S5-S9.
36. Wood PD, Stefanick ML, Dreon DM et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988; 319: 1171-1179.
37. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 397-415.
38. Aude YW, Mego P, Mehta JL. Metabolic syndrome: dietary interventions. Curr Opin Cardiol 2004; 19: 473-479.